Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was going to borrow your term for my reply but autocorrect fought me on it. My experience with that term was a former associate who expanded that to a whole phrase — as in. “ I’m not tryin to get in yer business but if it were me..........”
The steadiness at an elevated level has been impressive
If any positive news emerges indicating definitive progress on the FDA process it should ratchet up maybe even somewhere north of a dollar where I’d be content to see it hold until more positive news is generated.
FDA approval would of course should drive it up significantly although I wouldn’t expect the space shot another poster indicated was their selling price. I’ll be thrilled to see it become a viable product with steady growth tied to sales
I’m not intending to get in yer business but if it were me I’d get off your laptop and fire up the still to have some ethanol for my gas tank.
Apparently there are some different interpretations of break even among those who participate on this board.
Even if someone bought this stock as it was crashing, bought more to try to average down and then hung on through the reverse split, it doesn’t seem possible to be down approx. $250,000.20 per share. It’s conceivable to be down $25. 20 per share but not x10,000
I would say that payout is impossible ——but the Venezuela governing model does appear to be on the table so hyperinflation could get you to that price point but I wouldn’t call that a positive ending.
Maybe cashing out and buying a treasure map at a garage sale would be a better bet???
If this stock scares you put your money in something really stable. Like ???????
If this stock scares you put your money in something really stable. Like ???????
Anyone ever bought a car, and then wish you hadn’t ? —- didn’t like the dealer, didn’t like the way it drove —- did you you sell it and get something you were happy with or keep driving it just so you could rant about how awful it was?
Life is too short for that.
I thought USMA was the board moderator for this stock message board and now I see myjo is. Did it change as part of the pot at a card game or how does that work ? Hope you all were wearing 4 layers of masks or whatever the current guidelines were at the time. That’s a real advantage for those without a good poker face.
Doesn’t matter one way or the other just mildly curious about the message board politics. Very impressed however with the steady ratcheting up of this stock. A few more weeks of this and I may be crawling out of the hole I dug back before the reverse split.
It’s looking like the folks in Norcross Ga. actually have a viable product, they have survived the vicious cycles of undercapitalized startups and have almost made it thru the swamp of bureaucracy at the FDA which is stacked against them. I’d hate to see this stock price skyrocket and crash in a short term market feeding frenzy. That helps a few people who stay glued to the screen all day watching for the u-turn in pricing. Yes you can set a limit order and cash out if you are lucky enough to hit the sweet spot close to the peak but not over. This product is looking more and more like it’s capable of long term steady growth and maybe even dividends in a couple of years or a nice buy out price .
I’d like to think there is a substantial file of data too with test results similar to those discussed, but you would think that would have precipitated universities lining up to partner for a piece of the patent rights. They are all chasing patentable technology, crop varieties, medical devices/ procedures, nutritional products, .... think Gatorade. If this is the future of cancer screening and there is substantial confirmation of viability, financiers especially organizations ie hospital groups/ teaching hospitals capable of validating data internally should be competing for a chance to participate. I’m not knocking the management, they have kept a company going that could have failed a long time ago like thousands of other high risk high input cost startups. We should Actually be impressed with the longevity and persistence of gthp. Just unsure of why reputable third party validation of at least the concept being of interest hasn’t been publicized more.
FDA approval won’t be a quick or inexpensive exercise. An interim step to attract investors, partnerships and start some steady stock price growth would be a quick scaled up screening with a reputable hospital
I am obviously not a dr. but a “ less than full “ FDA evaluation would be pretty definitive one way And provide some much needed third party verification and publicity. If it failed what has mgt. or stockholders lost? Do something to ignite some market interest .
Again no medical expertise yet but proving something works in the marketplace doesn’t have to result in immediate regulatory approval and isn’t exclusive to this field.
Patients get screened for cervical cancer every week.
They need a cooperating hospital Preferably a reputable one, and 100 patients ( or 500) Willing to have an additional guided therapeutics screen in addition to the conventional method currently used.
For any patient results that don’t agree a third more conclusive screen is run to determine which was more accurate.
Results— gthp is either not as accurate, as accurate, or more accurate than the standard. This shouldn’t take a month to reach conclusions, and the data likely would be useful for the FDA file. If it’s positive this would generate great Verifiable PR, the type that would drive up stock prices. If it flops you can end the death of a thousand cuts and go invest in lottery tickets or blackjack instead of penny stocks for a while.
Time to do something conclusive.
Of course if we go to socialized medicine under the new administration there won’t be medical screenings for anyone except the deep state Bureaucrats and politicians which won’t be a very big market so maybe treading water until 2024 is a good strategy. I think I just talked myself into a trip to a casino with complimentary drinks and established odds.
This product does seem to have merit, and I know lots of products have gone unnoticed ... or suppressed for extended periods of time but this has been a long long haul with no progress.
That said I will repeat a couple of questions that one of the more brilliant posters slammed in the past as ignorant , thereby showing his own lack of knowledge.
Universities across the country including publicly funded ones are aggressively pursuing patentable research, many have the funding to pursue fda approval... or put together a group that does.
I can say I’d be thrilled if the Executives at guided therapeutics traded 40% -50% of the company to University of——— teaching hospital in exchange for conducting the required fda trials.
The positive impact of collaboration with a reputable institution alone would increase demand (= $) for the stock—- it would beat the hell out of the dilution used in the past to raise funds.
Has this been explored, and if not why?
Women’s health advocacy groups should be all over asking questions of public health officials to investigate and report on the validity of this product. Again, raising awareness and scrutiny will speed up all f us knowing if it is a valid product or not.
Like most of you longer term folks, my current stock value is small fraction of my investment, so selling out at this stage is pretty pointless, so it really needs to show real promise and start climbing out of the hole or go ahead and shut the doors. Permanently riding the bankruptcy line is a waste of everyone’s time.
That reference does not make you old
I keep waiting on Ed McMahon to roll up my drive with a check from the “ fruit” company that keeps getting mentioned as a potential buyer for all our stock. Should I go ahead and quit my day job?
Thank you for inadvertently helping make my points.
1. Large multi national companies have the capital and staying power to wade thru the bureaucratic process
Not so easily done by a start up especially in a highly regulated field like medical devices. Making an investment in a one product company like gthp with no major backing or cash flow from other product sales or corporate divisions even riskier. So accept the odds of success in penny stocks just like you do when you walk into a casino.
2. About the only thing most people can do to change the regulatory hurdles that keep many good start ups from succeeding is to voice the need for faster track alternatives( pros and cons to that too) to those who can make changes That would be your congressional representatives
3. Ranting at the CEO and other stockholders who would all like this to be successful too, doesn’t change anything
Making a reasoned argument to the right people for providing better ways for innovative and cost saving medical devices to become available might have a very slim chance of making a difference.
Anyone who plays Penny and especially sub penny stocks needs to accept the risk associated with them.
Odds on winning may actually be better at a casino, but nobody made you sit at either table. Occasionally with good research and a little luck you might hit on a cheap stock. Gthp appears to have a viable product but regulatory hurdles and lack of financing ( a result of the regulatory obstacles to getting in the market) have kept it in the gutter.
Suggestion to the whiners I have made before. Spend the time you take bashing the management everyday and redirect it at your US Representative and Senators. They have the ability to create flexibility at The FDA and fast track devices that show promise of benefiting millions of their constituents. So if you want to do something positive, focus on getting them to put innovative health care options ahead of their campaign accounts. Write to them not us!!
To all the optimists, pumping other stockholders hasn’t moved this, at least not since I’ve owned it
It looks like a legit product but that doesn’t make it successful, sales of the device bus the only thing that will
So instead of spending your endless telling us about the grand potential each of you spend your time contacting
Clinics, oncologists, teaching hospitals, health department officials and US senators and reps in your district to nudge the FDA
Spend your time showing the Gthp staff how to sell a product instead of hyping it to people who already have more invested in it than they want too.
Help yourself if you are so positive !!
Post from 2 weeks ago still Hollis. The frustration needs to be channeled not at the device innovators trying to find a market but at the fda bureaucracy and the politicians who have oversight for them.
A device like this should be permitted to be tried / demonstrated alongside approved devices by willing physicians ie simultaneous results on same( willing patients) as an initial step. Successful results would yield willing investors. Current approval methods screen out all but those with very deep pockets driving companies like gthp offshore where patent violations can easily occur along with non payment.
Fact is if FDA gave more leeway for free market experimental use of medical devices with simultaneous standard practice confirmation it wouldn’t be so prohibitly expensive to prove ( or disprove) a device’s value and risky foreign markets wouldn’t be the only route for under funded start ups.
Political bureaucracy prevents potentially patient benefiting technology from coming into play unless they have extremely deep pockets. There is a need for validation but validation shouldn’t be suffocating
If you believe the product is legit then your frustration should be directed at your US Rep. and Senators, not the cash strapped innovators.
Use this as an example with them as to why health care costs are thru the roof.
May not help gthp but it’s a good point to make with elected officials
If you are going to whine do so at the right target!!
https://pharmaphorum.com/news/luviva-scanner-could-provide-alternative-to-smear-test/
This should have been good enough press and been picked up by enough market watchers to level this stock out at a couple of cents for the rest of the year
But it obviously wasnt/ isn’t
Mentions in journals like that are exactly what they need— just being noted as a player in such a big market
If Gthp could get a little notice in the Atlanta news media for being a local innovator in improved cancer detection you’d have enough traction to stabilize and even improve investor confidence —- stock just needs to bump up a little and hold for while to let this play out
Open letter to executives of GTHP,
FDA approval is obviously what is needed and even if this device is an improved method of screening, approval is a costly process and squashing promising competition through bureaucratic means can be an added obstacle. If it is as promising as I thought it was when I started buying stock then it fading away will be a worse loss for those who will benefit from this technology than our financial setbacks.
Assuming it is as good as the reported data indicates ( 95+ % accuracy with quicker results and no biopsy) then some level of support should be forthcoming from reputable sources that would get the attention of investors and public health officials—- enough to rebound stock prices to a respectable level.
The FDA has been reported to be more open to fast tracking devices that benefit patients and bring down costs than it was under the previous administration.
Somewhere in this country there has To be some combination of one or more of a cancer clinic administrator, university research faculty member, public health official ( even at a state or local level), women’s health advocacy group, politician wanting to appear concerned about constituents( it is an election year). It is critical that finding and publicizing support from two or three such reputable individuals or organizations be the imediate priority of the executives of this company.
That is what will bring in investors, spur action by regulators and salvage this company ( if it actually worthy of it). Keep selling discounted notes and stock and waiting for the bureaucracy to work and this will fail, you don’t have the staying power. It needs more than a nudge, it needs a shove. Market the concept publicly with even tentative support from representatives of these groups and you may still succeed to the benefit of patients, stockholders and yourselves.
Stay on the current track and failure is sure.
No one is asking for fluff
A Reputable organization publically noting potential value ( and it could include weasel words like ‘ potential’
assuming adoption by medical personnel outside of US and the 95+% accuracy in US testing is all valid working a quote out of someone of substance shouldn’t be too tough — and enough to bump up the price a little and attract some solid financing — if that assumption isn’t correct then the ship keeps taking on water
The news doesn’t even have to be fda approval or anything even close
Just solid verifiable support from a reputable source
Even a mention of confidence that the technology shows great promise and needs to be fast tracked thru FDA
There is a long list of potential positive statement candidates
Hospital or clinic or single doctor that has focus on economical reliable screening
Public health department official federal ,state, even local
A university researcher. ( not data results just expression of interest— that goes for any of these)
A charitable organization / mission group working overseas or in poverty areas domestically wherevthis would have great benefits— SW Native American Reservstions, Appalachia for example
That would be enough to boost price a bit and attract solid financing
Don’t need a home run just a base hit or two to generate some crowd enthusiasm
Question for frankenvestors inquiry
If the fda data was that good ( 95+ %) and if there Are documented foreign users then gthp needs PR Dept help
Somewhere there is a woman’s health magazine, public health advocate, US representative or senator staff wanting it to look like their boss cares prior to midterm elections, NPR reporter covering ‘ women’s issues ‘ .....that could give a much needed boost to product awareness
I know they have phone service in Georgia
If there is substance to this product there is someone with a platform to raise interest and gthp should have found them by now. I’d say time is of the essence and they need to get on their game
No one made anybody buy stock, may have been deceived but that’s the market , big risk for big payoff just like a slot machine —wish all the snowflakes understood that too
https://nartc.fcm.arizona.edu/partnership-native-american-cancer-prevention-nacp
Here is an example of a university with existing funding looking for proposals to partner with
There are others and gthp has to do it not minor common stock holders , that said I’d rather see this succeed since I’m in the negative column on this stock
This is actually a pretty good fit — since you already have rapport with Gene you are in a better position to offer suggestions
Gthp is pretty far down the road with this and a partner such as this could move the needle even with a limited scale screening accuracy evaluation
The key is quick economical and accurate results if that can be demonstrated by a reputable institution domestically more funding will line up. And so what if it has to be some sort of split on revenue ?
Part of a lot beats all of nothing
That answers a lot of questions,
Thanks for chasing those down.
I don’t think he is following what you asked him on the teaching / research hospital question.
He is thinking gthp paying for additional studies and he doesn’t have the capital to do it.
Assuming this really is proven technology ( other country uses) there should be enough data to interest an institution flush with endowment money to finish up the testing for US approval in exchange for partial ownership
Selling more stock dilutes ownership more than an agreed to percentage with a teaching / research hospital does. And a deal with a university/ hospital provides instant boost in credibility ——-> rising stock prices
Gene has more to gain with that type deal ( with less risk ) than gambling that this thing stays afloat —- and so do the stockholders
Doesn’t much matter what either of us thinks but 100% of current revenues won’t buy you a beer much less anyone else. this needs a reputable partner to take it and make something happen. One that stands to gain handsomely, in this case with a university it would be $ and lots of good publicity if it proved successful
Grants are usually like the mythical free lunch. Look great until you feel the hook.
Whatever they do it needs to happen sooner than later or somebody picks it up as the company is liquidated
I still contend the best and quickest financing route would be a partnership with a university teaching hospital.
This assumes all the data on performance is accurate.
They finish up the testing, they add credibility and exposure all at the same time. In exchange they get a cut of the profits just like an investor.
If it’s all legitimate what university medical school wouldn’t want to be in on this ?
Clear concept the staff at gthp grasps I’m sure
Just ask the question
Maybe even some veterinarian applications for this device???
Almost every land grant university has eithe a medical or vet school affiliated with it Gthp staff should have contacts
Maybe one of you that communicates with Gene can push this angle as a possibility to put some long term life back into this product???
Why not a university partnership?
Maybe gthp has chased this but I’ve seen no mention of it on their site.
Many universities including public ones are strongly focused on obtaining patent rights for their research
If the data and performance of this unit are as good as indicated, entering into an agreement with a university teaching hospital to finish up the research for a piece of the ownership should be an option For something with this much potential to improve screening accuracy and economics it shouldn’t be a hard sell
With that kind of partnership, credibility would rise, progress would speed up and values rise accordingly
as the product proves itself .